Top

Published in:

29-04-2023 | Colectomy | Review

Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome

Authors: J. K. Stone, N. A. Mehta, H. Singh, W. El-Matary, C. N. Bernstein

Published in: Familial Cancer | Issue 4/2023

Abstract

Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome predisposing affected individuals to gastrointestinal (GI) cancers through a high burden of polyposis. Colorectal cancer rates reach 100% by the age of 45, making early colectomy a mainstay of treatment. While most patients undergo colectomy at an early age, ongoing screening and surveillance of the upper gastrointestinal tract and rectal pouch must continue throughout adulthood. Endoscopic therapy of gastric, duodenal, ampullary and rectal pouch polyps is critical to reduce morbidity and cancer related mortality. Management of these lesions is not uniform, and is dependent on their location, size, histology, and risk of malignant potential. Medical therapies targeting pathways that reduce the malignant progression of pre-cancerous lesions have been studied for many years. While studies on the use of aspirin and non-steroidal anti-inflammatories (NSAIDs) in chemoprevention have shown encouraging results in Lynch syndrome and primary colorectal cancer, the potential benefits of these medications have not been duplicated in FAP cohorts. While data remains limited on chemoprevention in FAP, a number of randomized trials are currently underway examining targeted therapies with the potential to slow the progression of the disease. This review aims to provide an in-depth review of the literature on current endoscopic options and chemopreventive therapies targeting FAP. While the endoscopic management has robust data for its use, chemoprevention in FAP is still in its infancy. The complementary use of chemopreventive agents and endoscopic therapy for FAP patients is quickly becoming a growing and exciting area of research.

Jasperson KW, Tuohy TM, Neklason DW, Burt RW (2010) Hereditary and familial colon cancer. Gastroenterology 138(6):2044–2058. https://doi.org/10.1053/j.gastro.2010.01.054CrossRefPubMed

Monahan KJ et al (2020) Guidelines for the management of hereditary colorectal cancer from the British society of gastroenterology (BSG)/association of coloproctology of great Britain and Ireland (ACPGBI)/United Kingdom cancer genetics group (UKCGG). Gut 69(3):411–444. https://doi.org/10.1136/gutjnl-2019-319915CrossRefPubMed

Yang J et al (2020) American society for gastrointestinal endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. Gastrointest Endosc 91(5):963-982.e2. https://doi.org/10.1016/j.gie.2020.01.028CrossRefPubMed

Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223–262. https://doi.org/10.1038/ajg.2014.435CrossRefPubMedPubMedCentral

Auth M, Septer S, Hawkins ÃJ, Durno ÃÃC, Latchford ÃA (2019) Management of familial adenomatous polyposis in children and adolescents : position paper from the ESPGHAN polyposis working group. J Pediatr Gastroenterol Nutr 68(3):428–441. https://doi.org/10.1097/MPG.0000000000002247CrossRefPubMed

Björk J et al (2001) Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene Mutations. Gastroenterology 121(5):1127–1135. https://doi.org/10.1053/gast.2001.28707CrossRefPubMed

Herzig D et al (2017) The American society of colon and rectal surgeons clinical practice guidelines for the management of inherited polyposis syndromes. Dis Colon Rectum 60(9):881–894. https://doi.org/10.1097/DCR.0000000000000912CrossRefPubMedPubMedCentral

Statements A (2019) Genetic / familial high-risk assessment : colorectal, version 2. 2019. J Natl Compr Cancer Netw 17(9):1032–1041. https://doi.org/10.6004/jnccn.2019.0044CrossRef

Yang J et al (2020) American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. Gastrointest Endosc 91(5):963-982.e2. https://doi.org/10.1016/j.gie.2020.01.028CrossRefPubMed

10.

11.

Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223–262. https://doi.org/10.1038/ajg.2014.435CrossRefPubMedPubMedCentral

12.

Stone JK, Bernstein CN, Singh H, El-Matary W (2021) Prevalence of gastroduodenal polyps in children with familial adenomatous polyposis. J Can Assoc Gastroenterol 4(5):e101–e109. https://doi.org/10.1093/jcag/gwaa040CrossRefPubMed

13.

Vasen HFA et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57(5):704–713. https://doi.org/10.1136/gut.2007.136127CrossRefPubMed

14.

Weiss JM et al (2021) Genetic/familial high-risk assessment: colorectal, version 1.2021 featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Net 19(10):1122–1132. https://doi.org/10.1164/jnccn.2021.0048CrossRef

15.

Koskenvuo L, Ryynänen H, Lepistö A (2020) Timing of prophylactic colectomy in familial adenomatous polyposis. Colorectal Dis 22(11):1553–1559. https://doi.org/10.1111/codi.15151CrossRefPubMed

16.

Neuman HB et al (2010) Risk-reducing surgery in FAP: role for surgeons beyond the incision. J Surg Oncol 101(7):570–576. https://doi.org/10.1002/jso.21556CrossRefPubMed

17.

Friederich P et al (2008) Risk of developing adenomas and carcinomas in the Ileal pouch in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 6(11):1237–1242. https://doi.org/10.1016/j.cgh.2008.06.011CrossRefPubMed

18.

Bülow S et al (2004) Duodenal adenomatosis in familial adenomatous polyposis. Gut 53(3):381–386. https://doi.org/10.1136/gut.2003.027771CrossRefPubMedPubMedCentral

19.

Bülow S et al (2012) Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous polyposis. Colorectal Dis 14(8):947–952. https://doi.org/10.1111/j.1463-1318.2011.02844.xCrossRefPubMed

20.

Campos FG, Martinez CAR, Sulbaran M, Bustamante-Lopez LA, Safatle-Ribeiro AV (2019) Upper gastrointestinal neoplasia in familial adenomatous polyposis: Prevalence, endoscopic features and management. J Gastrointest Oncol 10(4):734–744. https://doi.org/10.21037/jgo.2019.03.06CrossRefPubMedPubMedCentral

21.

Gallagher MC, Phillips RKS, Bulow S (2006) Surveillance and management of upper gastrointestinal disease in familial adenomatous polyposis. Fam Cancer 5(3):263–273. https://doi.org/10.1007/s10689-005-5668-0CrossRefPubMed

22.

Spigelman A, Williams C, Talbot I, Domizio P, Phillips R (1988) Upper gastrointestinal cancer in patients with familial adenomatous polyposis. The Lancet 334(8666):783–785CrossRef

23.

Hopper AD (2022) Role of endoscopy in patients with familial adenomatous polyposis. Frontline Gastroenterology 13(e1):E72–E79. https://doi.org/10.1136/flgastro-2022-102125CrossRefPubMedPubMedCentral

24.

Roos VH et al (2021) Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis. Gastrointest Endosc 93(2):457–466. https://doi.org/10.1016/j.gie.2020.05.065CrossRefPubMed

25.

Offerhaus GJ et al (1992) The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102(6):1980–1982. https://doi.org/10.1016/0016-5085(92)90322-pCrossRefPubMed

26.

Angsuwatcharakon P et al (2020) Management of ampullary adenomas in familial adenomatous polyposis syndrome: 16 years of experience from a tertiary cancer center. Gastrointest Endosc 92(2):323–330. https://doi.org/10.1016/j.gie.2020.02.040CrossRefPubMed

27.

Ramai D et al (2022) Endoscopic management of ampullary adenomas in familial adenomatous polyposis syndrome: a systematic review with pooled analysis. Dig Dis Sci 67(7):3220–3227. https://doi.org/10.1007/s10620-021-07132-wCrossRefPubMed

28.

Jagelman H, DeCosse DG, Busey JJ (1988) Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1(8595):1149–1151CrossRefPubMed

29.

Mankaney G et al (2017) Gastric cancer in FAP: a concerning rise in incidence. Fam Cancer 16(3):371–376. https://doi.org/10.1007/s10689-017-9971-3CrossRefPubMed

30.

Iwama T et al (2004) A clinical overview of familial adenomatous polyposis derived from the database of the polyposis registry of Japan. Int J Clin Oncol 9(4):308–316. https://doi.org/10.1007/s10147-004-0414-4CrossRefPubMed

31.

Attard TM et al (2004) Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol 99(4):681–686. https://doi.org/10.1111/j.1572-0241.2004.04115.xCrossRefPubMed

32.

Coffey A, Patel K, Quintanilla N, Kellermayer R, Wu H (2017) Fundic gland polyps in the pediatric population: clinical and histopathologic studies. Pediatr Dev Pathol 20(6):482–489. https://doi.org/10.1177/1093526617706816CrossRefPubMed

33.

Bianchi LK, Burke CA, Bennett AE, Lopez R, Hasson H, Church JM (2008) Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 6(2):180–185. https://doi.org/10.1016/j.cgh.2007.11.018CrossRefPubMed

34.

Calavas L, Rivory J, Hervieu V, Saurin J-C, Pioche M (2017) Macroscopically visible flat dysplasia in the fundus of 3 patients with familial adenomatous polyposis. Gastrointest Endosc 85(3):679–680. https://doi.org/10.1016/j.gie.2016.04.024CrossRefPubMed

35.

Das Kannathu N et al (2018) Worrisome endoscopic feature in the stomach of patients with familial adenomatous polyposis: the proximal white mucosal patch. Gastrointest Endosc 88(3):569–570. https://doi.org/10.1016/j.gie.2018.03.027CrossRef

36.

Koornstra JJ (2012) Small bowel endoscopy in familial adenomatous polyposis and Lynch syndrome. Best Pract Res Clin Gastroenterol 26(3):359–368. https://doi.org/10.1016/j.bpg.2012.01.022CrossRefPubMed

37.

Günther U, Bojarski C, Buhr HJ, Zeitz M, Heller F (2010) Capsule endoscopy in small-bowel surveillance of patients with hereditary polyposis syndromes. Int J Colorectal Dis 25(11):1377–1382. https://doi.org/10.1007/s00384-010-0982-xCrossRefPubMed

38.

Barkay O, Moshkowitz M, Fireman Z, Shemesh E, Goldray O, Revivo M, Kessler A, Halpern Z, Orr-Urtreger A, Arber N. Initial experience of videocapsule endoscopy for diagnosing small-bowel tumors in patients with GI polyposis syndromes. Gastrointest Endosc. 2005 Sep;62(3):448–52. https://doi.org/10.1016/s0016-5107.www.mosby.com/gie

39.

Schulmann K et al (2005) Feasibility and diagnostic utility of video capsule endoscopy for the detection of small bowel polyps in patients with hereditary polyposis syndromes. Am J Gastroenterol 100(1):27–37. https://doi.org/10.1111/j.1572-0241.2005.40102.xCrossRefPubMed

40.

Burke CA, Santisi J, Church J, Levinthal G (2005) The utility of capsule endoscopy small bowel surveillance in patients with polyposis. Am J Gastroenterol 100(7):1498–1502. https://doi.org/10.1111/j.1572-0241.2005.41506.xCrossRefPubMed

41.

Iaquinto G, Fornasarig M, Quaia M, Giardullo N (2008) Capsule endoscopy is useful and safe for small-bowel surveillance in familial adenomatous polyposis. Gastrointest Endosc 67(1):61–67. https://doi.org/10.1016/j.gie.2007.07.048CrossRefPubMed

42.

Tescher P et al (2010) Surveillance of FAP: A prospective blinded comparison of capsule endoscopy and other GI imaging to detect small bowel polyps. Hered Cancer Clin Pract. https://doi.org/10.1186/1897-4287-8-3CrossRefPubMedPubMedCentral

43.

Ruys AT, Alderlieste YA, Gouma DJ, Dekker E, Mathus-Vliegen EMH (2010) Jejunal cancer in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 8(8):731–733. https://doi.org/10.1016/j.cgh.2010.04.008CrossRefPubMed

44.

Alderlieste YA, Rauws EAJ, Mathus-Vliegen EMH, Fockens P, Dekker E (2013) Prospective enteroscopic evaluation of jejunal polyposis in patients with familial adenomatous polyposis and advanced duodenal polyposis. Fam Cancer 12(1):51–56. https://doi.org/10.1007/s10689-012-9571-1CrossRefPubMed

45.

Tacheci I, Kopacova M, Bures J (2021) Peutz-Jeghers syndrome. Curr Opi Gastroenterol 37(3):245–254. https://doi.org/10.1097/MOG.0000000000000718CrossRef

46.

Ishida H, Iwama T, Inokuma S, Takeuchi I, Hashimoto D, Miyaki M. APC gene mutations in a jejunal adenoma causing intussusception in a patient with familial adenomatous polyposis. J Gastroenterol. 2002;37(12):1057–61. https://doi.org/10.1007/s005350200178

47.

Katona BW, Weiss JM (2020) Chemoprevention of Colorectal Cancer. Gastroenterology 158(2):368–388. https://doi.org/10.1053/j.gastro.2019.06.047CrossRefPubMed

48.

Veettil SK, Lim KG, Ching SM, Saokaew S, Phisalprapa P, Chaiyakunapruk N (2017) Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. BMC Cancer 17(1):763. https://doi.org/10.1186/s12885-017-3757-8CrossRefPubMedPubMedCentral

49.

Burn J et al (2020) Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. The Lancet 395(10240):1855–1863. https://doi.org/10.1016/S0140-6736(20)30366-4CrossRef

50.

Lynch PM (2016) Chemoprevention of familial adenomatous polyposis. Familial Cancer 15(3):467–475. https://doi.org/10.1007/s10689-016-9901-9CrossRefPubMed

51.

Kemp Bohan PM et al (2021) Chemoprevention in familial adenomatous polyposis: past, present and future. Familial Cancer 20(1):23–33. https://doi.org/10.1007/s10689-020-00189-yCrossRefPubMed

52.

Burn J et al (2011) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4(5):655–665. https://doi.org/10.1158/1940-6207.CAPR-11-0106CrossRefPubMed

53.

Ishikawa H et al (2013) Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med 2(1):50–56. https://doi.org/10.1002/cam4.46CrossRefPubMedPubMedCentral

54.

McLean MH, Murray GI, Fyfe N, Hold GL, Mowat NAG, El-Omar EM (2008) COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics. Histopathology 52(7):806–815. https://doi.org/10.1111/j.1365-2559.2008.03038.xCrossRefPubMed

55.

Oshima M et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803–809. https://doi.org/10.1016/s0092-8674(00)81988-1CrossRefPubMed

56.

Eisinger AL et al (2006) The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. J Biol Chem 281(29):20474–20482. https://doi.org/10.1074/jbc.M602859200CrossRefPubMed

57.

Steinbach G et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946–1952. https://doi.org/10.1056/NEJM200006293422603CrossRefPubMed

58.

Phillips RKS et al (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50(6):857–860. https://doi.org/10.1136/gut.50.6.857CrossRefPubMedPubMedCentral

59.

Burke CA et al (2017) Children’s International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. Clin Exp Gastroenterol 10:177–185. https://doi.org/10.2147/CEG.S121841CrossRefPubMedPubMedCentral

60.

Labayle D et al (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101(3):635–639. https://doi.org/10.1016/0016-5085(91)90519-qCrossRefPubMed

61.

Waddell WR, Loughry RW (1983) Sulindac for polyposis of the colon. J Surg Oncol 24(1):83–87. https://doi.org/10.1002/jso.2930240119CrossRefPubMed

62.

Giardiello FM et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328(18):1313–1316. https://doi.org/10.1056/NEJM199305063281805CrossRefPubMed

63.

Giardiello FM et al (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346(14):1054–1059. https://doi.org/10.1056/NEJMoa012015CrossRefPubMedPubMedCentral

64.

Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RK (1995) Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 345(8953):855–856CrossRefPubMed

65.

Neuhann TM et al (2022) Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study. Fam Cancer. https://doi.org/10.1007/s10689-022-00292-2CrossRefPubMed

66.

Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA (1997) Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 57(2):199–201PubMed

67.

Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW (2008) Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr Cancer 60(Suppl 1):30–35. https://doi.org/10.1080/01635580802401317CrossRefPubMed

68.

Meyskens FL et al (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1(1):32–38. https://doi.org/10.1158/1940-6207.CAPR-08-0042CrossRefPubMed

69.

Lynch PM et al (2016) An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut 65(2):286–295. https://doi.org/10.1136/gutjnl-2014-307235CrossRefPubMed

70.

Hall MJ (2021) Updates in chemoprevention research for hereditary gastrointestinal and polyposis syndromes. Curr Treat Options Gastroenterol 19(1):30–46. https://doi.org/10.1007/s11938-020-00306-xCrossRefPubMed

71.

Burke CA et al (2020) Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis. N Engl J Med 383(11):1028–1039. https://doi.org/10.1056/NEJMoa1916063CrossRefPubMed

72.

Samadder NJ et al (2016) Effect of sulindac and erlotinib vs placebo: on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA - J Am Med Assoc 315(12):1266–1275. https://doi.org/10.1001/jama.2016.2522CrossRef

73.

Samadder NJ et al (2018) Association of Sulindac and Erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: secondary analysis of a randomized clinical trial. JAMA Oncol 4(5):671–677. https://doi.org/10.1001/jamaoncol.2017.5431CrossRefPubMedPubMedCentral

74.

Samadder NJ et al (2022) Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis. Gut. https://doi.org/10.1136/gutjnl-2021-326532CrossRefPubMed

75.

Wen F, Zheng H, Zhang P, Hutton D, Li Q (2018) OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. BMJ Open 84:e020128. https://doi.org/10.1136/bmjopen-2017-020128CrossRef

76.

Cruz-Correa M et al (2018) Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis. Gastroenterology 155(3):668–673. https://doi.org/10.1053/j.gastro.2018.05.031CrossRefPubMed

77.

West NJ et al (2010) Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 59(7):918–925. https://doi.org/10.1136/gut.2009.200642CrossRefPubMed

78.

Bussey HJ et al (1982) A randomized trial of ascorbic acid in polyposis coli. Cancer 50(7):1434–1439. https://doi.org/10.1002/1097-0142(19821001)50:7%3c1434::aid-cncr2820500733%3e3.0.co;2-fCrossRefPubMed

79.

Faller WJ et al (2015) mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature 517(7535):497–500. https://doi.org/10.1038/nature13896CrossRefPubMed

80.

Hardiman KM, Liu J, Feng Y, Greenson JK, Fearon ER (2014) Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model. PLoS One 9(4):e96023. https://doi.org/10.1371/journal.pone.0096023CrossRefPubMedPubMedCentral

81.

Roos VH et al (2020) Sirolimus for the treatment of polyposis of the rectal remnant and ileal pouch in four patients with familial adenomatous polyposis: a pilot study. BMJ Open Gastroenterol. https://doi.org/10.1136/bmjgast-2020-000497CrossRefPubMedPubMedCentral

82.

Clarke J et al (2023) Can butyrate prevent colon cancer? The AusFAP study: A randomised, crossover clinical trial. Contemp Clin Trials Commun. https://doi.org/10.1016/j.conctc.2023.101092CrossRefPubMedPubMedCentral

Title: Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome
Authors: J. K. Stone
N. A. Mehta
H. Singh
W. El-Matary
C. N. Bernstein
Publication date: 29-04-2023
Publisher: Springer Netherlands
Keywords: Colectomy
Colectomy
Celecoxib
Familial Adenomatous Polyposis
Colorectal Cancer
Colorectal Cancer
Published in: Familial Cancer / Issue 4/2023
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-023-00334-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

PREMM5 distinguishes sporadic from Lynch syndrome-associated MMR-deficient/MSI-high colorectal cancer

Prevalence and genetic spectrum associated with hereditary colorectal cancer syndromes, the need to improve cancer risk awareness, and family cascade testing in Vietnam

Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer

Unusual phenotypes in patients with a pathogenic germline variant in DICER1

Reclassification of two germline DICER1 splicing variants leads to DICER1 syndrome diagnosis

Balancing the burden and benefits of colonoscopy in Lynch Syndrome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer